Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome

Completed · Phase 1

Conditions studied: Angelman Syndrome

In brief

This study is designed to determine the highest dose of levodopa/carbidopa that can be tolerated without any serious side effects by children with Angelman syndrome. It has been hypothesized that levodopa may lead to an improvement in the neurodevelopment and abnormal movements (e.g. tremors) in children with Angelman syndrome. Data from this study will be used to design a phase II trial to determine the efficacy of levodopa in treating children with Angelman syndrome.

Key facts

Study ID
NCT00829439
Run by
Boston Children's Hospital
People needed
16
Starts
2009-01-01
Expected to finish
2010-06-01
Last updated by the study team
2016-11-21

Who can join

Age: 4 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.